The precise characterization of the m/z values of t-mAbs used in the treatment of MM and lymphomas represents a significant advancement for clinical laboratories, as it enables accurate discrimination of these t-mAbs from endogenous M-proteins in patients receiving immunotherapy. Here, MYOM2 is linked to lymphoma.